Quanterix (NASDAQ:QTRX) Stock Rating Lowered by Wall Street Zen

Quanterix (NASDAQ:QTRX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Quanterix in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $11.33.

Quanterix Trading Up 3.2%

Shares of QTRX stock opened at $6.80 on Friday. The company has a market cap of $317.63 million, a price-to-earnings ratio of -2.92 and a beta of 1.01. The stock has a 50 day simple moving average of $6.28 and a 200-day simple moving average of $5.80. Quanterix has a 12-month low of $4.05 and a 12-month high of $12.41.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.13). The business had revenue of $40.23 million during the quarter, compared to analysts’ expectations of $37.85 million. Quanterix had a negative net margin of 73.47% and a negative return on equity of 21.34%. On average, equities analysts forecast that Quanterix will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Quanterix

Institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its holdings in Quanterix by 9.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 292,805 shares of the company’s stock valued at $1,906,000 after acquiring an additional 26,190 shares in the last quarter. Invesco Ltd. increased its stake in shares of Quanterix by 61.0% during the 1st quarter. Invesco Ltd. now owns 54,194 shares of the company’s stock worth $353,000 after purchasing an additional 20,540 shares in the last quarter. Nuveen LLC purchased a new position in shares of Quanterix during the 1st quarter worth approximately $2,704,000. American Century Companies Inc. raised its position in shares of Quanterix by 9.9% during the 1st quarter. American Century Companies Inc. now owns 79,130 shares of the company’s stock worth $515,000 after purchasing an additional 7,138 shares during the last quarter. Finally, Quantbot Technologies LP lifted its stake in Quanterix by 245.9% in the 1st quarter. Quantbot Technologies LP now owns 11,272 shares of the company’s stock valued at $73,000 after buying an additional 8,013 shares in the last quarter. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.